Kunitoshi Shigeyasu

7PUBLICATIONS
8CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 18, 2026
EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti-Epidermal Growth Factor Receptor-Based Therapy in Metastatic Colorectal Cancer.

|Feb 27, 2026
Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness.

Yuki Matsumi, Kunitoshi Shigeyasu, Toshiaki Takahashi

|Jan 03, 2025
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients.

Toshiaki Takahashi, Kunitoshi Shigeyasu, Yoshitaka Kondo

|Jul 04, 2024
BRAF-mutant microsatellite-stable rectal cancer with acquired KRAS mutation leading to drug resistance in liver metastasis.

Kunitoshi Shigeyasu, Hideki Yamamoto, Toshiaki Takahashi

|Feb 06, 2023
ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer.

Nanako Hata, Kunitoshi Shigeyasu, Yuzo Umeda

|Dec 18, 2022
RNA Editing is a Valuable Biomarker for Predicting Carcinogenesis in Ulcerative Colitis.

Kazutaka Takahashi, Kunitoshi Shigeyasu, Yoshitaka Kondo

Pageof 2

Frequent Collaborators

2 joint publications

Ajay Goel

2 joint publications

Toshiaki Takahashi

2 joint publications

Toshiyoshi Fujiwara

1 joint publications

Kazuya Moriwake